{
  "id": "mesoblast-reports-ryoncil-net-revenues-of-us-30-m-for-the-quarter",
  "title": "Mesoblast reports Ryoncil® net revenues of US$30 M for the quarter",
  "summary": "Mesoblast Limited, a global developer of allogeneic cellular medicines, reported that its Ryoncil® (remestemcel‑L‑rknd) product generated net revenues of US$30 million for the quarter ended December 31, 2025, the company said. Ryoncil® gross sales for the period were US$35 million, representing a 60 percent increase from the prior quarter, reflecting rising commercial uptake following its U.S. Food and Drug Administration […] The post Mesoblast reports Ryoncil® net revenues of US$30 M for the quarter appeared first on Longevity.Technology.",
  "url": "https://longevity.technology/news/mesoblast-reports-ryoncil-net-revenues-of-us30-m-for-the-quarter/",
  "source": "Longevity.Technology",
  "author": null,
  "category": "news",
  "publishedAt": "2026-02-02T03:46:06.000Z",
  "fetchedAt": "2026-02-04T10:49:05.816Z",
  "relevanceScore": 0.2,
  "matchedKeywords": [
    "longevity"
  ],
  "relatedProducts": [],
  "type": "web",
  "savedAt": "2026-02-04T10:49:05.888Z"
}